SCHEMBL24349086

SCHEMBL24349086

CCOC(=O)c1csc(NC(=O)COc2ccc(Cl)cc2C)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 2/20 1.00
▸ LMNA P02545 3/20 0.85
▸ MAPK1 P28482 2/20 0.85
▸ MAPT P10636 3/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ CYP1A2 P05177 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ EGFR P00533 1/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ GAA P10253 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ TSHR P16473 3/20 0.52
▸ HPGD P15428 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ HSP90AA1 P07900 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546119 0.78 MAPK1 (0.69) ANO1LMNAMAPK1MAPTMEN1
SCHEMBL3605957 0.77 LMNA (0.68) ANO1LMNAMAPK1MAPTL3MBTL1
SCHEMBL3604421 0.77 LMNA (0.65) ANO1LMNAMAPK1MAPTL3MBTL1
SCHEMBL3608921 0.76 SMN1; SMN2 (0.78) ANO1LMNAMAPK1MAPTMEN1
SCHEMBL4720801 0.76 LMNA (0.61) ANO1LMNAMAPK1MAPTMEN1
SCHEMBL13438093 0.75 MAPT (0.64) ANO1MAPK1MAPTMEN1KMT2A
SCHEMBL24348596 0.75 RAB9A (0.73) ANO1MAPK1MAPTMEN1KMT2A
SCHEMBL4127691 0.74 CYP1A2 (0.76) ANO1LMNAMAPK1MAPTCYP1A2
SCHEMBL4723608 0.74 LMNA (0.59) ANO1LMNAMAPK1MAPTMEN1
SCHEMBL18015141 0.74 EGFR (0.64) ANO1LMNAMAPK1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274074-B2 Pharmaceutical composition for ANO1 antagonist with anticancer activity INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) 2022-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274074-B2 Pharmaceutical composition for ANO1 antagonist with anticancer activity ANO1, ANO2, TMEM109 ANO1 1/4885LMNA 3228/4885MAPK1 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback